Furthermore, a clinical trial involving 3,377 participants and a cohort study with 124,517 participants found that GLP-1 analogues were not associated with either suicidal ideation, depression, nor suicidal death [24, 25]. Here, GLP1R is linked to depressive symptom measurement.